Skip to main content

Author: Customer Service

Brag House Holdings, Inc. Announces Closing of Initial Public Offering

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) — Brag House Holdings, Inc. (“Brag House” or the “Company”), a premier media technology platform designed for casual college gamers and brands seeking to connect with the Gen Z demographic, today announced the closing of its initial public offering (the “Offering”) of 1,475,000 shares of its common stock at a public offering price of US$4.00 per share. Kingswood Capital Partners, LLC is acting as the Sole Bookrunning Manager and WestPark Capital Inc. is acting as an underwriter. Lucosky Brookman LLP is acting as U.S. securities counsel to the Company, and Dickinson Wright LLP is acting as U.S. securities counsel to the underwriters in connection for the Offering. A registration statement on Form S-1 (File No. 333-280282) relating to the Offering was filed...

Continue reading

Stran & Company Reports Financial Results for Three and Nine Months Ended September 30, 2024

– Granted Listing Extension from Nasdaq Hearing Panel – QUINCY, Mass., March 07, 2025 (GLOBE NEWSWIRE) — Stran & Company, Inc. (“Stran” or the “Company”) (NASDAQ: SWAG) (NASDAQ: SWAGW), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today provided a business update and reported financial results for the three and nine months ended September 30, 2024. On March 3, 2025, the Nasdaq Hearings Panel informed the Company that it determined to grant the request of Stran to continue its listing on Nasdaq subject to three conditions. The first was that the Company become current on its financial filings, which the Company has met as of today through the filing of its Form 10-Q for the third quarter of 2024. The second was...

Continue reading

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) — Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that it has notified the Nasdaq Stock Market (“Nasdaq”) of its decision to delist the Company’s shares of common stock, par value $0.0001 per share (the “Common Stock”), from Nasdaq. Trading in the Common Stock on Nasdaq has been suspended since December 18, 2024. Vaccinex intends to file a Form 25 with the Securities and Exchange Commission on or about March 17, 2025 to remove its Common Stock from listing on Nasdaq. The Company’s decision to delist follows its receipt of notice dated December 16, 2024, that the...

Continue reading

Orezone Gold Files Final Short Form Prospectus in Connection With C$35 Million Bought Deal

Final Short Form Prospectus is accessible on SEDAR+ NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, March 07, 2025 (GLOBE NEWSWIRE) — Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (the “Company” or “Orezone”) is pleased to announce that, further to its press release dated February 23, 2025 in respect of its bought deal offering of common shares of the Company (the “Common Shares”), it has filed a final short form prospectus dated March 7, 2025 (the “Final Prospectus”) with the securities commissions in all provinces of Canada, except Quebec, and has obtained a receipt therefor. The Final Prospectus qualifies the distribution of 42,683,000 Common Shares at a price of C$0.82 per Common Share (the “Offering Price”) for aggregate gross proceeds of C$35,000,060...

Continue reading

Methanex Releases 2024 Sustainability Report

VANCOUVER, British Columbia, March 07, 2025 (GLOBE NEWSWIRE) — Methanex Corporation (TSX:MX) (Nasdaq:MEOH) released its 2024 Sustainability Report today to share its progress on the sustainability topics that are most material to the company and its stakeholders. “I am proud of our global team’s commitment to safety and Responsible Care® and our best-ever safety performance achievement in 2024. Our safety performance puts us in the top ten per cent for safety performance among the American Chemistry Council’s Responsible Care members.1 The Sustainability Report outlines Methanex’s 2024 activities, including how we protect and develop our people, minimize our impact on the environment and contribute to our communities.” said Rich Sumner, President and CEO of Methanex. “I am pleased to report on our progress towards fulfilling our...

Continue reading

Grupo Aeroportuario del Pacifico, S.A.B. de C.V. General Ordinary Shareholders’ Meeting

GUADALAJARA, Mexico, March 07, 2025 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announced the following: Pursuant to a resolution adopted by our board of directors on February 24, 2025, and in accordance with Articles 180, 181, 182 and other applicable articles of the Mexican General Corporate Law and Article 35 of the Company’s by-laws, Grupo Aeroportuario del Pacífico, S.A.B. de C.V. invites its shareholders to the General Ordinary Shareholders’ Meeting on April 24, 2025 at 12:00 p.m. in Ballroom 3, 3rd floor of the Hilton Midtown Hotel, located at Av. López Mateos 2405-300, Col. Italia Providencia, Guadalajara, Jalisco, Mexico, to discuss the following: ANNUAL GENERAL ORDINARY SHAREHOLDERS’ MEETINGAGENDA I. In compliance with Article 28, Section IV of the...

Continue reading

Constellation Software Inc. Announces Results for the Fourth Quarter and Year Ended December 31, 2024 and Declares Quarterly Dividend

TORONTO, March 07, 2025 (GLOBE NEWSWIRE) — Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) today announced its financial results for the fourth quarter and year ended December 31, 2024 and declared a $1.00 per share dividend payable on April 15, 2025 to all common shareholders of record at close of business on March 28, 2025. This dividend has been designated as an eligible dividend for the purposes of the Income Tax Act (Canada). Please note that all dollar amounts referred to in this press release are in U.S. Dollars unless otherwise stated. The following press release should be read in conjunction with the Company’s annual Consolidated Financial Statements, prepared in accordance with IFRS Accounting Standards (“IFRS”) and our annual Management’s Discussion and Analysis for the year ended December 31,...

Continue reading

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

SAN FRANCISCO, March 07, 2025 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 2024. “We expect to receive 24-week topline data from our Phase 2b ASPIRE study in diabetic macular edema (DME) in this quarter,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “DME remains a significant unmet need, and we believe UBX1325 (foselutoclax) has the potential to provide a differentiated treatment option for patients who continue to experience vision loss despite current standard-of-care therapies. With its novel mechanism of action and durable therapeutic profile, UBX1325 could offer meaningful advantages over existing anti-VEGF...

Continue reading

Blueberries Medical Announces C$1 Million Non-Brokered Private Placement

TORONTO, March 07, 2025 (GLOBE NEWSWIRE) — Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or “Blueberries“), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce a non-brokered private placement consisting of the sale of 96,064,935 common shares (“Common Shares”) at a price of C$0.011 per Common Share for aggregate gross proceeds of approximately C$1.05 million (or approximately US$740,000) (the “Offering”). The net proceeds from the sale of the Common Shares are expected to fund and expand operations, for general corporate and working capital purposes. The Offering is expected to close on or about March 25, 2024. It is expected that the Offering will be led by Terraflos Inc. (“Terraflos”), a cannabis company with operations throughout...

Continue reading

S&P Global Ratings affirms Iceland at ‘A+/A-1’, Outlook Stable

S&P Global Ratings has affirmed ‘A+/A-1’ long- and short-term foreign and local currency sovereign credit ratings on Iceland. The outlook is stable. S&P´s ratings on Iceland reflect the country’s very high GDP per capita and strong growth track record, which has been higher than most sovereigns S&P rates in Western Europe, as well as Iceland’s robust institutional framework and sound economic and fiscal policies. The ratings remain constrained by the volatile nature of Iceland’s small, open economy, which, in S&P’s view, is vulnerable to natural events, including volcanic activity, as well as adverse external developments outside of its control, such as geopolitical risks, trade and tariff tensions, and fluctuating terms-of-trade. The small size of Iceland’s economy also somewhat limits...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.